NR1H4 and myeloid sarcoma: Bhargava et al. performed cellular experiments and found that bile acid receptor expression was enhanced in immune and neuroglial cells from MS patients, and supplementation of cells and mice with TUDCA revealed that TUDCA alleviated symptoms in MS patients by modulating the bile acid receptor G protein-coupled bile acid receptor 1 (GPBAR1; Bhargava et al., 2020).